Summary of COVID-19 SNS812 studies
Hide extended summaries
RCT 135 patients with mild to moderate COVID-19 showing significant efficacy of aerosolized siRNA SNS812 in reducing viral load and accelerating symptom resolution. The trial randomized patients to 200mg, 100mg, or placebo arms, with treatment initiated within 3 days of symptom onset. The 200mg group demonstrated significantly faster viral clearance and greater viral load reduction starting from day 1. Symptom improvement showed dose-dependent effects with significant reduction in time to resolution for 6 of 14 symptoms, including shortness of breath and loss of taste/smell. Authors do not provide enough information on symptomatic outcomes for meta analysis. The siRNA targets a highly conserved region of the viral RNA-dependent RNA polymerase gene and showed efficacy against multiple Omicron variants.
Mar 2025, CROI 2025, https://www.croiconference.org/wp-content/uploads/sites/2/posters/2025/158-2025.pdf, https://c19p.org/chang10
1. Chang et al., Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: A Phase II Trial
90 patient SNS812 early treatment RCT: 17% improved viral clearance (p=0.02).RCT 135 patients with mild to moderate COVID-19 showing significant efficacy of aerosolized siRNA SNS812 in reducing viral load and accelerating symptom resolution. The trial randomized patients to 200mg, 100mg, or placebo arms, with treatment initiated within 3 days of symptom onset. The 200mg group demonstrated significantly faster viral clearance and greater viral load reduction starting from day 1. Symptom improvement showed dose-dependent effects with significant reduction in time to resolution for 6 of 14 symptoms, including shortness of breath and loss of taste/smell. Authors do not provide enough information on symptomatic outcomes for meta analysis. The siRNA targets a highly conserved region of the viral RNA-dependent RNA polymerase gene and showed efficacy against multiple Omicron variants.
Mar 2025, CROI 2025, https://www.croiconference.org/wp-content/uploads/sites/2/posters/2025/158-2025.pdf, https://c19p.org/chang10
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.